Egalet Raises Series B

Egalet AS, a Danish drug company focused on the development of oral controlled-release products, has raised $27.6 million in Series B funding. Atlas Venture and Index Ventures co-led the deal, and were joined by return backers Bio Fund, Dansk Kapitalanl